The SPRAVATO REMS programme, explained

What the programme asks of you

You will be enrolled in the REMS programme by the treatment centre before your first dose. Enrolment is a form, completed with the site — there is nothing you need to do in advance, and nothing you need to pay for it.

At each session, the same things happen: you self-administer the spray while a healthcare professional watches, your blood pressure is checked before and after, and you stay on site for at least two hours while they observe you. You are discharged when the clinician judges you ready, not at a fixed time. Someone else drives you home.

What you sign, and why

The enrolment paperwork records that the risks have been explained to you — principally sedation, dissociation, blood-pressure increases, and the potential for misuse — and that you understand the monitoring and no-driving requirements. It also allows the programme to record that you are receiving the medication, which is how the FDA tracks that the safety conditions are actually being met.

The part that surprises people

The two-hour monitoring period is not negotiable and is not shortened because you feel fine. It applies to every session, including your twentieth. Neither is the driving restriction: the label instructs that you not drive or operate machinery until the day after the dose, following restful sleep. Both of these are conditions of the drug being available at all, which is a reasonable trade but is easier to accept when you know about it before you book.

What certification covers

Certification under the SPRAVATO REMS applies to the healthcare setting, not to an individual prescriber alone. The setting designates an authorised representative, and prescribers and staff who will supervise administration complete the programme's training. The pharmacy that supplies the product must also be certified, and product is shipped only to certified settings.

Your obligations once certified

• Verify the patient is enrolled before dispensing or administering.
• Ensure every dose is self-administered by the patient under direct observation.
• Monitor the patient on site for at least two hours after each dose, including blood-pressure assessment, and document it.
• Confirm the patient is accompanied or has arranged transport, and counsel on the driving restriction.
• Maintain the records the programme requires and remain available for programme audit.

Where the official forms are

Enrolment and certification forms are hosted by the REMS programme itself. Use the programme's own copies — the SPRAVATO REMS site↗ (opens in a new tab) has the current versions.

We deliberately do not host or mirror those forms here. A regulatory form that has been copied to a third-party site and then not updated is a genuine hazard: someone completes a superseded version, the submission is rejected or, worse, accepted with the wrong attestations. The official copy is one click away and is always current. That is the right place to get it.

It is easy to read REMS as bureaucracy. It is more useful to read it as a description of the drug's actual risk profile.

Esketamine can cause sedation and dissociation — a temporary sense of being detached from yourself or your surroundings — which typically begin shortly after dosing and resolve over the following couple of hours. It can raise blood pressure, sometimes substantially, in the period after a dose. And as a Schedule III controlled substance, it carries potential for misuse.

Each REMS requirement maps onto one of those. Supervision covers self-administration and misuse. The two-hour window covers sedation, dissociation, and the blood-pressure peak. The driving restriction covers the tail of the sedation. Site certification is what makes all of it enforceable.

Framed that way, the programme is the reason this drug is available outside a hospital at all.